EVMN revenueQ2 2026$0
- FY YoY
- +85.7%
EVMN revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $13.00M, up 85.7% from fiscal 2024.
Evommune Inc. (EVMN) financials
For the twelve months ended Jun 30, 2026, Evommune Inc. reported $10.00M of revenue and -$94.67M of net income.
- Revenue, TTM
- $10.00M
- Net income, TTM
- -$94.67M
- Net margin
- -946.7%
- Free cash flow, TTM
- -$74.65M
- Cash
- $60.03M
- P/S
- 32.35
- Market cap
- $323.5M
FY2024FY2025
FY2024FY2025
FY2024FY2025
EVMN revenue and earnings growth
EVMN net incomeQ2 2026-$32.25M
EVMN net income was -$32.25M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$13.56M a year earlier. For the full fiscal 2025 it was -$68.87M, compared with -$66.81M in fiscal 2024.
EVMN EPSQ2 2026-$0.89
EVMN diluted EPS was -$0.89 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$11.22.
EVMN free cash flowQ2 2026-$20.50M
EVMN free cash flow was -$20.50M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$26.21M a year earlier. For the full fiscal 2025 it was -$76.68M, compared with -$58.28M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Revenue | $13.00M | $7.00M |
| Research and development | $74.04M | $64.24M |
| Selling, general and admin | $20.03M | $12.77M |
| Operating income | -$81.07M | -$70.01M |
| Pre-tax income | -$68.87M | -$68.31M |
| Income tax | $0 | $0 |
| Net income | -$68.87M | -$66.81M |
| EPS, basic | -$11.22 | -$45.29 |
| EPS, diluted | -$11.22 | -$45.29 |
| Diluted shares | 6.1M | 1.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $44.06M | $16.46M |
| Short-term investments | $105.14M | $55.78M |
| Current assets | $153.48M | $73.99M |
| Total assets | $224.95M | $76.06M |
| Current liabilities | $17.91M | $27.98M |
| Total liabilities | $19.38M | $28.52M |
| Shareholders' equity | $205.57M | -$144.24M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$76.44M | -$58.20M |
| Capital expenditures | $235.0K | $88.0K |
| Free cash flow | -$76.68M | -$58.28M |
| Investing cash flow | -$115.31M | -$3.99M |
| Financing cash flow | $220.76M | $49.42M |
| Stock-based compensation | $5.86M | $1.72M |
| Depreciation and amortization | $600.0K | $500.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $10.00M | $0 | $3.00M | $0 | - |
| Research and development | $26.41M | $17.32M | $20.40M | $19.64M | $19.64M | $14.36M | $17.83M | $13.29M |
| Selling, general and admin | $8.48M | $6.63M | $9.31M | $3.69M | $3.36M | $3.67M | $3.62M | $3.23M |
| Operating income | -$34.90M | -$23.95M | -$29.72M | -$13.33M | -$22.99M | -$15.03M | -$21.45M | -$16.52M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$32.25M | -$21.67M | -$28.27M | -$12.47M | -$13.56M | -$14.56M | -$20.73M | -$15.92M |
| EPS, basic | -$0.89 | -$0.64 | - | -$8.07 | -$8.80 | -$9.48 | - | -$10.47 |
| EPS, diluted | -$0.89 | -$0.64 | - | -$8.07 | -$8.80 | -$9.48 | - | -$10.47 |
| Diluted shares | 36.1M | 33.7M | - | 1.5M | 1.5M | 1.5M | - | 1.5M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $60.03M | $48.32M | $44.06M | $26.82M | $61.84M | $5.70M | $16.46M | $18.15M |
| Short-term investments | $140.76M | $163.15M | $105.14M | $49.24M | - | - | $55.78M | - |
| Current assets | $204.25M | $215.85M | $153.48M | $81.94M | - | - | $73.99M | - |
| Total assets | $301.95M | $322.45M | $224.95M | $84.54M | - | - | $76.06M | - |
| Current liabilities | $17.49M | $10.60M | $17.91M | $10.42M | - | - | $27.98M | - |
| Total liabilities | $24.36M | $17.90M | $19.38M | $10.68M | - | - | $28.52M | - |
| Shareholders' equity | $277.59M | $304.56M | $205.57M | -$183.14M | -$171.23M | -$158.24M | -$144.24M | -$122.53M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.32M | -$27.50M | -$16.70M | -$9.63M | -$26.21M | -$23.90M | -$18.51M | - |
| Capital expenditures | $183.0K | $83.0K | $104.0K | $131.0K | $0 | $0 | $0 | - |
| Free cash flow | -$20.50M | -$27.59M | -$16.80M | -$9.77M | -$26.21M | -$23.90M | -$18.51M | - |
| Investing cash flow | $31.29M | -$85.36M | -$122.90M | -$23.91M | $18.00M | $13.50M | -$33.08M | - |
| Financing cash flow | $532.0K | $117.11M | $156.85M | -$274.0K | $64.34M | -$152.0K | $49.70M | - |
| Stock-based compensation | $4.60M | $3.45M | $4.20M | $560.0K | $556.0K | $544.0K | $494.0K | - |
| Depreciation and amortization | $200.0K | $100.0K | -$463.0K | $763.0K | $200.0K | $200.0K | -$427.0K | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | - | - | - | - | - | - |
| Operating margin | - | - | - | -133.3% | - | -501.1% | - | - |
| Net margin | - | - | - | -124.8% | - | -485.2% | - | - |
| Free cash flow margin | - | - | - | -97.7% | - | -796.6% | - | - |
| Current ratio | 11.68 | 20.36 | 8.57 | 7.87 | - | - | 2.64 | - |
Source: XBRL data Evommune Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
EVMN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| EVMN | $10.00M | - | -$94.67M | -946.7% | $323.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
EVMN FAQ
7 questionsWhat is EVMN revenue?
Evommune Inc. (EVMN) reported $10.00M of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $13.00M.Is EVMN profitable?
No. Evommune Inc. reported a net loss of $94.67M for the twelve months ended Jun 30, 2026.How much cash and debt does EVMN have?
Evommune Inc. reported $60.03M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is EVMN revenue growing?
Evommune Inc.'s revenue changed +85.7% in fiscal 2025, to $13.00M.What is EVMN free cash flow?
Evommune Inc. generated -$74.65M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$74.15M less capital expenditures.When did EVMN last report financial results?
The latest statements here come from Evommune Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this EVMN financial data come from?
Quantisnow builds these statements from the structured XBRL data Evommune Inc. files with the SEC. It is provided for information only and is not investment advice.